Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML.

ABSTRACT:

Background

Venetoclax monotherapy is an effective option for patients with acute myeloid leukemia (AML). Venetoclax has also been used in non-myeloablative conditioning allogeneic hematopoietic stem cell transplantation (allo-HSCT) for high-risk AML with a tolerable toxicity profile. However, the efficacy and safety of a venetoclax-containing myeloablative conditioning (MAC) allo-HSCT regimen for high-risk AML have not been evaluated.

Objective

To evaluate the safety and efficacy of a MAC regimen containing venetoclax for high-risk AML.

Study design

From 25 February 2021 to 4 September 2022, a total of 31 patients with high-risk AML who underwent allo-HSCT and a MAC regimen with venetoclax were analyzed.

Results

At the time of transplantation, 21 patients were

SUBMITTER: Cao XY 

PROVIDER: S-EPMC9851264 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature